Sign In
Buy CDNA
$22.07
-0.730 (-3.20%)
At Close: Jun 02, 2026
CareDx Reports Preliminary Financial Results for Third Quarter 2024
06:00am, Tuesday, 15'th Oct 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of cl
NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 11'th Oct 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx Appoints Jing Huang Chief Data and AI Officer
07:05am, Wednesday, 09'th Oct 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx to Host Investor Day on October 15, 2024
04:05pm, Tuesday, 08'th Oct 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
06:05am, Tuesday, 08'th Oct 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2
12:06pm, Wednesday, 02'nd Oct 2024
Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93.
NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
07:32pm, Sunday, 29'th Sep 2024
CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's product
Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund.
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:35pm, Friday, 13'th Sep 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:33pm, Friday, 13'th Sep 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
10:15am, Friday, 09'th Aug 2024
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 07'th Aug 2024
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
09:05pm, Wednesday, 31'st Jul 2024
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
